Research Article| Volume 19, ISSUE 1, P139-147, January 1997

Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone

  • Stephen M. Aronson
    Address correspondence to: Stephen Aronson, MD, Department of Medical Education-Psychiatry, Oakwood Hospital and Medical Center, Medical Office Building, Suite 401, 18181 Oakwood Blvd., Dearborn, MI 48124.
    Department of Medical Education-Psychiatry, Oakwood Hospital and Medical Center, Dearborn U.S.A.
    Department of Medical Education-Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan U.S.A.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      Schizophrenia is arguably the worst disease affecting humankind, costly in both social and financial terms. In the current cost-cutting climate, the focus is on economizing the delivery of health care, including reducing access to prescription drugs. Yet decreasing expenditures on drugs for severe illnesses, such as schizophrenia, is a false economy. Drugs account for only a small proportion of the total costs of treating schizophrenia, with inpatient hospital care comprising the greatest portion of total treatment costs. Thus the use of risperidone, a more effective but more expensive antipsychotic medication, can decrease the total cost of care for patients with chronic schizophrenia by decreasing the need for hospitalization. Fewer days spent in the hospital also often means a better quality of life for patients. This finding is illustrated by case histories of 3 patients, 2 with schizophrenia and 1 elderly patient with behavioral disturbances of dementia


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Anonymous. Opinion. Where next with psychiatric illness.
        Nature. 1988; 336: 95-96
        • Miller LS
        • Kelman S
        Estimates of the loss of individual productivity from alcohol and drug abuse and from mental illness.
        in: Frank RG Manning WG Economics and Mental Health. Johnson Hopkins University Press, Baltimore, Md1992: 91-129
      2. Decision Resources.
        Depressive Disorders: Cognos Study #8; Pharmacor: Cognos. Decision Resources, Burlington, Mass1992
        • Terkelsen KG
        • Menihoff A
        Measuring the cost of schizophrenia: Implication for the post-institutional era in the U.S..
        PharmacoEconomics. 1995; 8: 199-222
        • Lindström E
        • Eriksson B
        • Hellgren A
        • et al.
        Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia.
        Clin Ther. 1995; 17: 402-412
        • Geller JL
        A report on the “worst” state hospital recidivists in the US.
        Community Psychiatry. 1992; 43: 904-908
        • Greenberg PE
        • Stiglin LE
        • Finkelstein SN
        • Berndst ER
        The economic burden of depression in 1990.
        J Clin Psychiatry. 1993; 54: 405-418
        • Soumerai SB
        • Ross-Degnan D
        • Avorn J
        • et al.
        Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes.
        NEJM. 1991; 325: 1072-1077
        • Soumerai SB
        • McLaughlin TJ
        • Ross-Degnan D
        • et al.
        Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizoprenia.
        NEJM. 1994; 331: 650-655
        • Addington DE
        • Jones B
        • Bloom D
        • et al.
        Reduction of hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study.
        Clin Ther. 1993; 15: 917-926
        • Guest JF
        • Hart WM
        • Cookson R
        • Lindström E
        Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia.
        Br J Med Econ. 1996; 10: 59-67
        • Albright PS
        • Livingstone S
        • Keegan DL
        • et al.
        Reduction in healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with antipsychotic therapy.
        Clin Drug Invest. 1996; 11: 289-298
        • Plosker GL
        Risperidone—does it give enough bang for the buck.
        Inpharma. 1994; (April): 7-8
        • Meltzer HY
        • Cola P
        • Way L
        • et al.
        Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia.
        Am J Psychiatry. 1993; 150: 1630-1638
        • Sanchez LA
        Evaluating the quality of published pharmacoeconomic evaluations.
        Hosp Pharm. 1995; 30: 146-153
        • Laupacis A
        • Wong C
        • Churchill D
        • et al.
        The use of generic and specific quality of life measures in hemodialysis patients treated with erythropoietin.
        Control Clin Trials. 1991; 12 (Suppl 4): 1685-1795
        • Mancetti JD
        • Hoffman LA
        • Sereika SM
        • et al.
        Quality of life in lung transplant candidates: Effect of education plus exercises vs. education alone.
        Am Rev Respir Dis. 1992; 145 (Abstract): A477
        • Marder SR
        • Meibach RC
        Risperidone in the treatment of schizophrenia.
        Am J Psychiatry. 1994; 151: 825-835
      3. IMS data, February 1996.

        • Aronson SM
        • Lingham V
        • Stadi M
        Treating elderly psychiatric patients with risperidone.
        149th annual meeting of the American Psychiatric Association. 491996; (Presented at the) (New York)
        • Goldberg J
        Risperidone for dementia-related disturbed behavior in nursing home residents: A clinical experience.
        148th annual meeting of the American Psychiatric Association. 21241995; (Presented at the) (Washington, DC)
        • Jeste DV
        • Eastham JH
        • Lacro JP
        • et al.
        Management of late-life psychosis.
        J Clin Psychiatry. 1996; 57 (Suppl 3): 39-45
        • Reisberg B
        • Borenstein J
        • Salob SP
        • et al.
        Behavioral symptoms of Alzheimer's disease: Phenomenology and treatment.
        J Clin Psychiatry. 1987; 48 (Suppl): 9-15
        • Reisberg B
        • Franssen E
        • Sclan SG
        • et al.
        Stage specific incidents of potentially remediable behavioral symptoms in aging and Alzheimer's disease: A study of 120 patients using the BEHAVE-AD.
        Bull Clin Neurosci. 1989; 54: 95-112
        • Reisberg B
        • Ferris SH
        • Torossian C
        • et al.
        Pharmacologic treatment of Alzheimer's disease: A methodologic critique based upon current knowledge of symptomatology and relevance for drug trials.
        Int Psychogeriatr. 1992; 4: 9-42
        • Cohen-Mansfield J
        Assessment of disruptive behavior/agitation in the elderly: Function, methods, and difficulties.
        J Geriatr Psychiatry Neurol. 1995; 8: 52-60
        • Ferris SH
        • Steinberg G
        • Shulman E
        • et al.
        Institutionalization of Alzheimer's disease patients: Reducing precipitating factors through family counseling.
        Home Health Care Serv Q. 1987; 8: 23-51
        • Sanford J
        Tolerance of disability in elderly dependents by supporters at home: Its significance for hospital practice.
        BMJ. 1975; 3: 471-473